Hormone therapy and heart disease

Obstetrics and Gynecology

Volumn 121, Issue 6, 2013, Pages 1407-1410

[No Author Info available]

Author keywords

[No Author keywords available]

Indexed keywords

ESTROGEN;

AGE DISTRIBUTION; CARDIOVASCULAR RISK; CLINICAL TRIAL; DISEASE DURATION; ESTROGEN THERAPY; HEART DISEASE; HORMONAL THERAPY; HUMAN; MENOPAUSE; PRIORITY JOURNAL; REVIEW; AGE; ARTICLE; CORONARY ARTERY DISEASE; FEMALE; MIDDLE AGED; PRACTICE GUIDELINE;

AGE FACTORS; CORONARY DISEASE; ESTROGEN REPLACEMENT THERAPY; FEMALE; HUMANS; MIDDLE AGED;

EID: 84879091272     PISSN: 00297844     EISSN: 1873233X     Source Type: Journal    
DOI: 10.1097/01.AOG.0000431053.33593.2d     Document Type: Review

References (33)

1. Barrett-Connor E, Bush TL. Estrogen and coronary heart disease in women. JAMA 1991;265:1861-7.
2. Grady D, Rubin SM, Petitti DB, Fox CS, Black D, Ettinger B, et al. Hormone therapy to prevent disease and prolong life in postmenopausal women. Ann Intern Med 1992;117: 1016-37.
3. Barrett-Connor E, Grady D. Hormone replacement therapy, heart disease, and other considerations. Annu Rev Public Health 1998;19:55-72.
4. Grodstein F, Manson JE, Colditz GA, Willett WC, Speizer FE, Stampfer MJ. A prospective, observational study of postmenopausal hormone therapy and primary prevention of cardiovascular disease. Ann Intern Med 2000;133:933-41.
5. Psaty BM, Heckbert SR, Atkins D, Lemaitre R, Koepsell TD, Wahl PW, et al. The risk of myocardial infarction associated with the combined use of estrogens and progestins in postmenopausal women. Arch Intern Med 1994;154:1333-9.
6. Sidney S, Petitti DB, Quesenberry CP Jr. Myocardial infarction and the use of estrogen and estrogen-progestogen in postmenopausal women. Ann Intern Med 1997;127:501-8.
7. Stampfer MJ, Colditz GA. Estrogen replacement therapy and coronary heart disease: a quantitative assessment of the epidemiologic evidence. Prev Med 1991;20:47-63.
8. Stampfer MJ, Willett WC, Colditz GA, Rosner B, Speizer FE, Hennekens CH. A prospective study of postmenopausal estrogen therapy and coronary heart disease. N Engl J Med 1985;313:1044-9.
9. Rossouw JE, Anderson GL, Prentice RL, LaCroix AZ, Kooperberg C, Stefanick ML, et al. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results From the Women's Health Initiative randomized controlled trial. Writing Group for the Women's Health Initiative Investigators. JAMA 2002;288:321-33.
10. Hulley S, Grady D, Bush T, Furberg C, Herrington D, Riggs B, et al. Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women. Heart and Estrogen/progestin Replacement Study (HERS) Research Group. JAMA 1998;280:605-13.
11. Grady D, Herrington D, Bittner V, Blumenthal R, Davidson M, Hlatky M, et al. Cardiovascular disease outcomes during 6.8 years of hormone therapy: Heart and Estrogen/progestin Replacement Study follow-up (HERS II). HERS Research Group [published erratum appears in JAMA 2002;288:1064].
12. JAMA 2002;288:49-57.
13. Barrett-Connor E. Hormones and heart disease in women: the timing hypothesis. Am J Epidemiol 2007;166:506-10.
14. Manson JE, Bassuk SS. Invited commentary: hormone therapy and risk of coronary heart disease why renew the focus on the early years of menopause? Am J Epidemiol 2007;166:511-7.
15. Hsia J, Langer RD, Manson JE, Kuller L, Johnson KC, Hendrix SL, et al. Conjugated equine estrogens and coronary heart disease: the Women's Health Initiative. Women's Health Initiative Investigators [published erratum appears in Arch Intern Med 2006;166:759].
16. Arch Intern Med 2006; 166:357-65.
17. Simon JA, Hsia J, Cauley JA, Richards C, Harris F, Fong J, et al. Postmenopausal hormone therapy and risk of stroke: The Heart and Estrogen-progestin Replacement Study (HERS). Circulation 2001;103:638-42.
18. Anderson GL, Limacher M, Assaf AR, Bassford T, Beresford SA, Black H, et al. Effects of conjugated equine estrogen in postmenopausal women with hysterectomy: the Women's Health Initiative randomized controlled trial. Women's Health Initiative Steering Committee. JAMA 2004;291: 1701-12.
19. Manson JE, Hsia J, Johnson KC, Rossouw JE, Assaf AR, Lasser NL, et al. Estrogen plus progestin and the risk of coronary heart disease. Women's Health Initiative Investigators. N Engl J Med 2003;349:523-34.
20. Rossouw JE, Prentice RL, Manson JE, Wu L, Barad D, Barnabei VM, et al. Postmenopausal hormone therapy and risk of cardiovascular disease by age and years since menopause [published erratum appears in JAMA 2008; 299:1426].
21. JAMA 2007;297:1465-77.
22. Manson JE, Allison MA, Rossouw JE, Carr JJ, Langer RD, Hia J, et al. Estrogen therapy and coronary-artery calcification. WHI and WHI-CACS Investigators. N Engl J Med 2007;356:2591-602.
23. Allison MA, Manson JE, Langer RD, Carr JJ, Rossouw JE, Pettinger MB, et al. Oophorectomy, hormone therapy, and subclinical coronary artery disease in women with hysterectomy: the Women's Health Initiative coronary artery calcium study. Women's Health Initiative and Women's Health Initiative Coronary Artery Calcium Study Investigators. Menopause 2008;15:639-47.
24. Bernstein P, Pohost G. Progesterone, progestins, and the heart. Rev Cardiovasc Med 2010;11:228-36.
25. Rosano GM, Webb CM, Chierchia S, Morgani GL, Gabraele M, Sarrel PM, et al. Natural progesterone, but not medroxyprogesterone acetate, enhances the beneficial effect of estrogen on exercise-induced myocardial ischemia in postmenopausal women. J Am Coll Cardiol 2000;36: 2154-9.
26. Rylance PB, Brincat M, Lafferty K, De Trafford JC, Brincat S, Parsons V, et al. Natural progesterone and antihypertensive action. Br Med J (Clin Res Ed) 1985;290:13-4.
27. Lee DY, Kim JY, Kim JH, Choi DS, Kim DK, Koh KK, et al. Effects of hormone therapy on ambulatory blood pressure in postmenopausal Korean women. Climacteric 2011; 14:92-9.
28. Fahraeus L, Larsson-Cohn U, Wallentin L. L-norgestrel and progesterone have different influences on plasma lipoproteins. Eur J Clin Invest 1983;13:447-53.
29. Effects of hormone replacement therapy on endometrial histology in postmenopausal women. The Postmenopausal Estrogen/Progestin Interventions (PEPI) Trial. The Writing Group for the PEPI Trial. JAMA 1996;275:370-5.
30. Greenblatt RB, Gambrell RD Jr, Stoddard LD. The protective role of progesterone in the prevention of endometrial cancer. Pathol Res Pract 1982;174:297-318.
31. Moyer DL, de Lignieres B, Driguez P, Pez JP. Prevention of endometrial hyperplasia by progesterone during long-term estradiol replacement: influence of bleeding pattern and secretory changes. Fertil Steril 1993;59:992-7.
32. National Institutes of Health. ELITE: Early Versus Late Intervention Trial With Estradiol. Available at: http://clinicaltrials.gov/ct2/show/ NCT00114517. Retrieved March 25, 2013.
33. American Geriatrics Society updated Beers Criteria for potentially inappropriate medication use in order adults. American Geriatrics Society 2012 Beers Criteria Update Expert Panel. J Am Geriatr Soc 2012;60:616-31. Available at: http://www.americangeriatrics.org/files/documents/beers/2012BeersCriteria- JAGS.pdf. Retrieved March 29, 2013.